NA
Navellier & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $272K | Hold |
12,524
| – | – | 0.03% | 273 |
|
|
2025
Q1 | $304K | Sell |
12,524
-1,639
| -12% | -$39.8K | 0.04% | 254 |
|
|
2024
Q4 | $296K | Buy |
14,163
+1,869
| +15% | +$39K | 0.04% | 277 |
|
|
2024
Q3 | $244K | Sell |
12,294
-1,698
| -12% | -$33.8K | 0.03% | 294 |
|
|
2024
Q2 | $217K | Buy |
13,992
+164
| +1% | +$2.54K | 0.03% | 320 |
|
|
2024
Q1 | $220K | Sell |
13,828
-140,449
| -91% | -$2.24M | 0.03% | 317 |
|
|
2023
Q4 | $2.59M | Buy |
154,277
+17,663
| +13% | +$297K | 0.39% | 80 |
|
|
2023
Q3 | $1.6M | Buy |
136,614
+11,170
| +9% | +$131K | 0.27% | 97 |
|
|
2023
Q2 | $1.69M | Buy |
125,444
+718
| +0.6% | +$9.65K | 0.33% | 91 |
|
|
2023
Q1 | $2.07M | Buy |
124,726
+15,240
| +14% | +$253K | 0.44% | 83 |
|
|
2022
Q4 | $2.04M | Buy |
109,486
+4,448
| +4% | +$82.7K | 0.41% | 78 |
|
|
2022
Q3 | $1.35M | Buy |
+105,038
| New | +$1.35M | 0.3% | 91 |
|